3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Authors
Category Primary study
JournalBlood
Year 2023
This article has no abstract
Epistemonikos ID: 346db8896146156d18dc4caed343b65d3f22bd96
First added on: Feb 17, 2025